Atara BiotherapeuticsATRA -3.13%31 Gross Margin % is 75.97% as of Mar. 2026, which is 8% below its 10-year median of 82.44. GuruFocus rates ATRA with a GF Score™ of 31/100 and a GF Value™ of $1.56 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 737 Biotechnology companies, Atara Biotherapeutics ranks better than 94.17% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Atara Biotherapeutics had a gross margin of 75.97% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Atara Biotherapeutics Gross Margin % Related Terms
Atara Biotherapeutics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Atara Biotherapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATRA vs RNTX, IBIO, OSTX: Gross Margin % Comparison
For the Biotechnology subindustry, Atara Biotherapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atara Biotherapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Atara Biotherapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Atara Biotherapeutics (ATRA) has a Gross Margin % of 75.97% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Atara Biotherapeutics and its competitors. This is near median its historical median of 82.44. According to the industry distribution chart, Atara Biotherapeutics ranks #43 out of 737 companies in the Biotechnology industry, placing it in the top 5.8%.
Is Atara Biotherapeutics' Gross Margin % too high?
Atara Biotherapeutics' current Gross Margin % of 75.97% is near median its 10-year median of 82.44. The Biotechnology industry median Gross Margin % is 60.92. Atara Biotherapeutics' value of 75.97% is 24.7% above this industry median. Based on the distribution chart, Atara Biotherapeutics ranks #43 out of 737 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Atara Biotherapeutics has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Atara Biotherapeutics' Gross Margin % compare to RNTX and IBIO?
According to the Biotechnology industry distribution chart, Atara Biotherapeutics ranks #43 out of 737 companies for Gross Margin %. This places Atara Biotherapeutics in the top 6% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.92. Atara Biotherapeutics' value of 75.97% is 24.7% above this benchmark. While the company's 10-year median is 82.44 vs. the industry median of 60.92, Atara Biotherapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atara Biotherapeutics's current Gross Margin % of 75.97% is 24.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Atara Biotherapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atara Biotherapeutics's current Gross Margin % is 75.97%, which is near median its own 10-year median of 82.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atara Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Atara Biotherapeutics (ATRA) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.56, compared to a current price of $10.14 — trading 550% above its estimated fair value. The current Gross Margin % is 75.97%, which is near median its 10-year median of 82.44 and 24.7% above the Biotechnology industry median of 60.92. Atara Biotherapeutics' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Atara Biotherapeutics (ATRA), the current Gross Margin % is 75.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Atara Biotherapeutics (ATRA) Overvalued in 2026?
Based on GuruFocus' analysis, Atara Biotherapeutics stock appears to be overvalued.
The current stock price of $10.14 is trading 550% above its estimated GF Value™ of $1.56.
GuruFocus considers Atara Biotherapeutics to be Significantly Overvalued.
Key valuation signals for ATRA:
Gross Margin %: 75.97% (near median its 10-year median of 82.44)
GF Value™: $1.56 vs. price of $10.14 (550% above fair value)
Industry Position: 24.7% above the Biotechnology median (#43 of 737)
No single metric tells the full story. See the ATRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
31GF Score
Get the complete analysis for ATRA
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATRA has been successfully added to your 
